LEADER 02290nmm a2200493 u 4500
001 EB001957605
003 EBX01000000000000001120507
005 00000000000000.0
007 cr|||||||||||||||||||||
008 210211 ||| eng
100 1 |a Holgate, S. T. 
245 0 0 |a Update on the SNG001 drug, an INFbeta therapy for COVID-19  |h Elektronische Ressource  |c an interview with Stephen Holgate 
246 3 1 |a Update on the SNG001 drug, an INFβ therapy for COVID-19 
246 3 1 |a Update on the SNG001 drug, an Interferon-beta therapy for COVID-19 
260 |a London  |b Henry Stewart Talks  |c 2020, 2020 
300 |a 1 streaming audio file (13 min.)) 
505 0 |a An overview of SNG001 therapy -- Findings of the phase 2 clinical trial -- Treatment potential at different stages of the disease -- Advantages of the treatment delivery mode and accessibility -- Potential use as a prophylaxis treatment -- Follow up clinical trials to be undertaken -- Other treatment settings for INFβ 
653 |a Interferon-beta / administration & dosage 
653 |a severe acute respiratory syndrome coronavirus 2 
653 |a Pneumonia, Viral / drug therapy 
653 |a Clinical Trials, Phase II as Topic 
653 |a Pneumonia, Viral / prevention & control 
653 |a COVID-19 (Disease) / Prevention 
653 |a Precision Medicine 
653 |a Clinical trials 
653 |a Treatment Outcome 
653 |a Coronavirus infections / drug therapy 
653 |a COVID-19 / prevention & control 
653 |a Nebulizers and Vaporizers 
653 |a COVID-19 (Disease) / Treatment 
653 |a Antiviral agents / Development 
653 |a Coronavirus infections / prevention & control 
653 |a Interferon 
653 |a Antiviral Agents / administration & dosage 
653 |a Interferon-beta / therapeutic use 
653 |a COVID-19 / drug therapy 
653 |a Coronavirus infections / Chemotherapy 
041 0 7 |a eng  |2 ISO 639-2 
989 |b HST  |a Henry Stewart Talks 
490 0 |a Research and clinical interviews 
500 |a Audio interview. - Title from title frames. - Mode of access: World Wide Web 
856 4 0 |u https://hstalks.com/bs/4467  |x Verlag  |z Streaming video file 
856 4 2 |u https://hstalks.com/bs/p/1060  |3 Series 
082 0 |a 570